Irinotecan and Cisplatin for Advanced Lung Cancer
Author Information
Author(s): N. Masudal, M. Fukuoka, S. Kudohl, Y. Kusunoki, K. Matsui, N. Takifuji, K. Nakagawa, M. Tamanoil, T. Nitta, T. Hirashimal, S. Negoro, M. Takadal
Primary Institution: Osaka Prefectural Habikino Hospital
Hypothesis
What is the maximum tolerated dose of CPT-11 in combination with cisplatin for patients with advanced lung cancer?
Conclusion
The study found that the combination of CPT-11 and cisplatin resulted in an overall response rate of 43% with diarrhea being the main dose-limiting toxicity.
Supporting Evidence
- Diarrhea was the principal dose-limiting toxicity observed in the study.
- An overall response rate of 43% was achieved among the patients.
- One complete response and five partial responses were recorded.
- The maximum tolerated dose for future studies was recommended to be 80 mg m-2 of CPT-11.
Takeaway
Doctors tested a new cancer treatment using two drugs and found that it helped some patients, but it also caused a lot of diarrhea.
Methodology
Patients received escalating doses of CPT-11 along with a fixed dose of cisplatin, and their responses and toxicities were monitored.
Limitations
The study had a small sample size and was limited to previously untreated patients.
Participant Demographics
{"total_patients":14,"sex":{"male":8,"female":6},"age":{"median":61,"range":"43-74"},"performance_status":{"0-1":10,"2":4},"stage":{"IIIB":7,"IV":7}}
Statistical Information
P-Value
0.0027
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website